Enterome Overview
- Year Founded
-
2008
- Status
-
Private
- Employees
-
78
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$19M
- Investors
-
17
Enterome General Information
Description
Developer of pharmaceuticals and diagnostic tests designed for developing off-the-shelf, transformational cancer treatments targeting all tumor types. The company's approach generates a powerful, long-lasting immune response from the patient's own effector memory T-cells, overcoming the immune tolerance to self-antigens, integrated with a research and development platfo, with therm potential to deliver multiple candidates with a rapid progression, overcoming the immune tolerance to self-antigens, enabling healthcare companies to begin treatment more quickly and resulting in a likelihood of successful treatment.
Contact Information
Website
www.enterome.comCorporate Office
- 94/96 avenue Ledru-Rollin
- 75011 Paris
- France
Corporate Office
- 94/96 avenue Ledru-Rollin
- 75011 Paris
- France
Enterome Timeline
Enterome Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 13. Later Stage VC | 12-Jun-2025 | $19M | Completed | Clinical Trials - Phase 2 | ||
| 12. Accelerator/Incubator | 30-Oct-2023 | Completed | Clinical Trials - Phase 2 | |||
| 11. Later Stage VC (Series F) | 25-Oct-2023 | Completed | Clinical Trials - Phase 2 | |||
| 10. Accelerator/Incubator | 11-May-2023 | Completed | Clinical Trials - Phase 2 | |||
| 9. Later Stage VC | 19-Jul-2022 | Completed | Clinical Trials - Phase 2 | |||
| 8. Later Stage VC (Series E) | 25-Jun-2020 | Completed | Clinical Trials - Phase 1 | |||
| 7. Later Stage VC | 23-Oct-2018 | Completed | Clinical Trials - Phase 1 | |||
| 6. Later Stage VC (Series D) | 23-Nov-2017 | Completed | Clinical Trials - Phase 1 | |||
| 5. Later Stage VC (Series C) | 20-Apr-2016 | $16.4M | $42.3M | Completed | Clinical Trials - Phase 1 | |
| 4. Later Stage VC (Series B) | 01-May-2014 | $13.8M | $25.9M | Completed | Startup |
Enterome Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| P3 Shares | ||||||||
| Ordinary | ||||||||
| P3 Shares | ||||||||
| P2 Shares | ||||||||
| P2 Shares | ||||||||
| P2 Shares | ||||||||
| P1 Shares | 3,750,000 | $0.392203 | $2.06 | $2.06 | 1x | $2.06 | 19.38% | |
| P Shares | 825,000 | $0.392203 | $1.88 | $1.88 | 1x | $1.88 | 4.26% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Enterome Comparisons
Industry
Financing
Details
Enterome Competitors (34)
One of Enterome’s 34 competitors is Mnemo Therapeutics, a Venture Capital-Backed company based in Paris, France.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Mnemo Therapeutics | Venture Capital-Backed | Paris, France | ||||
| 4D pharma | Corporation | Leeds, United Kingdom | ||||
| SynDevRx | Venture Capital-Backed | Cambridge, MA | ||||
| Biotecnol | Formerly VC-backed | London, United Kingdom | ||||
| Iovance Biotherapeutics | Corporation | San Carlos, CA |
Enterome Patents
Enterome Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4499678-A1 | Antigenic peptides for prevention and treatment of cancer | Pending | 31-Mar-2022 | ||
| US-20250205324-A1 | Antigenic peptides for prevention and treatment of cancer | Pending | 31-Mar-2022 | ||
| WO-2023187127-A1 | Antigenic peptides for prevention and treatment of cancer | Inactive | 31-Mar-2022 | ||
| AU-2023246941-A1 | Antigenic peptides for prevention and treatment of cancer. | Pending | 31-Mar-2022 | ||
| AU-2022318248-A1 | Il-10 inducing polypeptides and uses thereof | Active | 27-Jul-2021 | C07K14/245 |
Enterome Signals
Enterome Investors (17)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Institute for Follicular Lymphoma Innovation | Not-For-Profit Venture Capital | Minority | ||
| Nestlé | Corporation | Minority | ||
| Primo Capital (Milano) | Venture Capital | Minority | ||
| Therapy Acceleration Program (TAP) | Not-For-Profit Venture Capital | Minority | ||
| Matwin | Accelerator/Incubator |
Enterome Investments (1)
Enterome’s most recent deal was a Joint Venture with Microbiome Diagnostics Partners. The deal was made on 11-Jul-2017.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Microbiome Diagnostics Partners | 11-Jul-2017 | Joint Venture | Diagnostic Equipment |
Enterome FAQs
-
When was Enterome founded?
Enterome was founded in 2008.
-
Where is Enterome headquartered?
Enterome is headquartered in Paris, France.
-
What is the size of Enterome?
Enterome has 78 total employees.
-
What industry is Enterome in?
Enterome’s primary industry is Drug Discovery.
-
Is Enterome a private or public company?
Enterome is a Private company.
-
What is Enterome’s current revenue?
The current revenue for Enterome is .
-
How much funding has Enterome raised over time?
Enterome has raised $292M.
-
Who are Enterome’s investors?
Institute for Follicular Lymphoma Innovation, Nestlé, Primo Capital (Milano), Therapy Acceleration Program (TAP), and Matwin are 5 of 17 investors who have invested in Enterome.
-
Who are Enterome’s competitors?
Mnemo Therapeutics, 4D pharma, SynDevRx, Biotecnol, and Iovance Biotherapeutics are some of the 34 competitors of Enterome.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process